BOSTON, Sept. 8, 2018 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, presented its preliminary clinical data of a first-in-class
Growth Capitalist (https://growthcapitalist.com/2018/09/carsgen-presents-car-claudin18-2-t-data-at-2018-car-tcr-summit/)
BOSTON, Sept. 8, 2018 /PRNewswire/ -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, presented its preliminary clinical data of a first-in-class